Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palonosetron oral - Roche/Helsinn Healthcare

Drug Profile

Palonosetron oral - Roche/Helsinn Healthcare

Alternative Names: Aloxi Capsule

Latest Information Update: 17 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharma Europe; Helsinn; Sinclair IS Pharma
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 17 Mar 2020 Helsinn announces intention to submit MAA to National Medical Products Administration for Chemotherapy-induced nausea and vomiting (Prevention) in China (Helsinn Healthcare pipeline, March 2020)
  • 01 Mar 2020 Clinical trials in Chemotherapy-induced nausea and vomiting (Prevention) in China (PO) before March 2020 (Helsinn Healthcare pipeline, March 2020)
  • 31 May 2017 No recent reports on development identified - Registered for Chemotherapy induced nausea and vomiting (Prevention) in Iceland and Liechtenstein (PO)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top